Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2020; 12(10): 1195-1208
Published online Oct 15, 2020. doi: 10.4251/wjgo.v12.i10.1195
Published online Oct 15, 2020. doi: 10.4251/wjgo.v12.i10.1195
Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis
Lang-Qing Sheng, Ling Liu, Qi Zhang, Xiao-Li Li, Yang-Nian Wei, Hui Luo, Cheng-Hui Zhou, Ze-Guo Chen, Nian-Feng Li, Department of Hepatobiliary and Pancreatic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Jia-Rong Li, Department of Biliopancreatic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Hao Qin, Da-Dong Zhang, Xiao-Ya Xu, Zi-Shuo Chen, Ji-Yang Zhang, Hao Chen, Fu-Gen Li, Research and Development Institute of Precision Medicine, 3D Medicines Inc., Shanghai 201114, Hunan Province, China
Meng-Li Huang, The Medical Department, 3D Medicines Inc., Shanghai 201114, China
Author contributions: Li NF, Sheng LQ, Li JR, Qin H, and Zhang DD designed the experiments; Li NF, Sheng LQ, Li JR, Qin H, Liu L, Zhang DD, Zhang Q, Huang ML, Xu XY, Li XL, Chen ZS, Wei YN, Luo H, Zhou CH, Chen ZG, and Li FG performed the experiments and interpreted the data; Li NF, Qin H, Zhang DD, Zhang JY, and Chen H carried out data analysis; Li NF, Sheng LQ, Li JR, Qin H, and Zhang DD wrote and revised the manuscript.
Institutional review board statement: The study was approved by the ethics committee of Xiangya Hospital and informed consent was obtained from all patients or their relatives.
Conflict-of-interest statement: All authors with 3D Medicines affiliation are current or former employees. No potential conflicts of interest are disclosed by the other authors.
Data sharing statement: The data used to support the findings of this study are available from the corresponding author upon request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nian-Feng Li, MD, Department of Hepatobiliary and Pancreatic Surgery, Xiangya Hospital of Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. 1535909540@qq.com
Received: June 2, 2020
Peer-review started: June 2, 2020
First decision: July 21, 2020
Revised: August 4, 2020
Accepted: August 31, 2020
Article in press: August 31, 2020
Published online: October 15, 2020
Processing time: 134 Days and 0.5 Hours
Peer-review started: June 2, 2020
First decision: July 21, 2020
Revised: August 4, 2020
Accepted: August 31, 2020
Article in press: August 31, 2020
Published online: October 15, 2020
Processing time: 134 Days and 0.5 Hours
Core Tip
Core Tip: To identify the potential biomarkers for hepatocellular carcinoma (HCC) diagnosis, we focused on exosomal micro ribonucleic acids (miRNAs) using miRNA sequencing. To our knowledge, this is the first study to explore the exosomal miRNAs for differential diagnosis of HCC using miRNA sequencing. This study provided a hint that blood exosomal miRNAs can be used as new non-invasive diagnostic tools for HCC in clinical implementation.